Abstract
Abstract An oral controlled-release morphine sulfate tablet (MS Contin) was evaluated for efficacy and safety in advanced cancer patients with significant pain. Results supported the safety and efficacy of every-12-hours dosing with this drug. The mean daily morphine requirements of these patients was large (444.7 ± 96.7 mg) but not significantly greater than that required when treated with immediate-release oral morphine sulfate dosed every four hours. The global impression of patients and investigators was that this sustained-release sulfate preparation was better regarding analgesia and side effects relative to immediate release oral morphine and other prior analgesics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
